- POSITIVE
Quarterly Revenue Innovision Jun-2026 Quarterly Revenue is Rs 267 Cr which is growth of 19.2% YoY.
- NEGATIVE
Quarterly Net Profit Innovision Jun-2026 Quarterly Net Profit is Rs -7 Cr which is growth of -152.4% YoY.
NSE: INNOVISION | BSE: 544732
Innovision Live Share Price Today, Share Analysis and Chart
aboutInnovision Ltd. is an integrated pharmaceutical company with a focus on the manufacturing and marketing of a diverse range of pharmaceutical products. The company operates across multiple segments of the pharmaceutical value chain, including Contract... Read More
258.3727.12(11.73%)
53,015
NSE+BSE Volume
NSE 02 Nov, 2026 3:31 PM (IST)
Slowing Down StockThese stocks have medium financials and valuations, but weak momentum indicating decreasing investor interestView SimilarEmbed DVM
Please subscribe to view forecaster data
Innovision Stock Price Analysis
Day Price Range11.7% 1 Day return | 258.4 (LTP) 232.8265.9 LowHigh |
|---|---|
Week Price Range36.2% 1 Week return | 258.4 (LTP) 179.1265.9 LowHigh |
Month Price Range2.1% 1 Month return | 258.4 (LTP) 179.1265.9 LowHigh |
52 Week Price Range-50.2% 1 Year return | 258.4 (LTP) 179.1470 LowHigh |
Competitors/Peers
Revenue Mix
Quarterly
Annual
Balance Sheet
Ratios
Cash Flow
Documents
Innovision quarterly results: revenue, profit, and P&L – 13 quarter history
Nested row level
Base Level
Reporting Type
Standalone
Cell Data
Actual
Table Settings
YoY & New to Old
Nested row level
Base Level
Export
| Indicator | Graph | Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 |
|---|---|---|---|---|---|---|---|
| 267.3 | 267.5 | 234.7 | 258.9 | 224.2 | 252.5 | ||
Operating Exp. | 273.2 | 248.9 | 222.4 | 245 | 206.7 | 231.5 | |
Operating Profit | -9.5 | 17.3 | 10.8 | 11.9 | 16.3 | 20.2 | |
Operating Profit Margin % | -3.59% | 6.50% | 4.64% | 4.64% | 7.32% | 8.02% | |
Depr. | 0.5 | 0.6 | 0.5 | 0.5 | 0.5 | 0.7 | |
Interest | 3.4 | 3.7 | 3.6 | 3 | 2.8 | 3.5 | |
Profit Before Tax | -9.9 | 14.3 | 8.2 | 10.3 | 14.2 | 16.8 | |
Tax | -3.2 | 2.4 | 3.6 | 2.1 | 1.4 | 5.6 | |
Net Profit | -6.7 | 11.9 | 4.6 | 8.2 | 12.8 | 11.3 | |
EPS Adj. latest | -2.8 | 5 | 1.9 | 3.5 | 5.4 | 4.7 | |
Net profit TTM | 18.1 | 37.6 | 36.9 | - | - | - | |
Basic EPS TTM | 7.6 | 15.8 | 19.5 | - | - | - | |
Earnings Transcripts | |||||||
Results PDF | |||||||
Result Notes |
*All financials are in INR Cr and price data in INR
Add metric to table
Search...
Innovision Technical Analysis
Innovision EMA & SMA
Bullish+5
6 bullish, 1 bearish
Bullish6
Bearish1
| 5 Day | 225.6 |
|---|---|
| 10 Day | 221.6 |
| 12 Day | 222.6 |
| 20 Day | 228.6 |
| 26 Day | 232.8 |
|---|---|
| 50 Day | 245.8 |
| 100 Day | 265.5 |
Innovision Delivery And Volume
Daily Avg. Delivery Volume %
02 Nov, 202642.7%
Week44.9%
Month54.8%
Legend
Positive IndicatorNeutral IndicatorNegative Indicator
Innovision Resistance and Support
252.36
Pivot
| First Resistance | 271.9 |
|---|---|
| Second Resistance | 285.5 |
| Third Resistance | 305 |
| First Support | 238.8 |
|---|---|
| Second Support | 219.3 |
| Third Support | 205.7 |
| Day RSI | 60.5 |
|---|---|
| Day MACD | -10.2 |
| Day MFI | 62.7 |
| Day MACD Signal Line | -12.1 |
Innovision Beta
| 1 Month | 2.7 |
|---|---|
| 1 Year | - |
| 3 Month | 1.3 |
|---|---|
| 3 Year | - |
Innovision Price Change Analysis
↑2.1%
Over 1 Month
LowHigh
179.1265.9
↓-9.5%
Over 3 Months
LowHigh
179.1296.7
↓-20.0%
Over 6 Months
LowHigh
179.1332.5
↓-50.2%
Over 1 Year
LowHigh
179.1470
Innovision Deals - Insider, Bulk, Block and SAST
| Client Name | Deal Type | Action | Date | Avg. Price | Quantity | Exchange |
|---|---|---|---|---|---|---|
| HRTI PRIVATE LIMITED | Bulk | Sell | 21 Apr 2026 | 353.65 | 99,817 | NSE |
| NEOMILE CORPORATE ADVISORY LIMITED | Bulk | Sell | 21 Apr 2026 | 387.05 | 235,029 | NSE |
| NEOMILE CORPORATE ADVISORY LIMITED | Bulk | Purchase | 21 Apr 2026 | 356.54 | 149,861 | NSE |
| HRTI PRIVATE LIMITED | Bulk | Purchase | 21 Apr 2026 | 359.50 | 132,085 | NSE |
| PALAK TRADELINK PRIVATE LIMITED | Bulk | Sell | 20 Apr 2026 | 327.70 | 130,000 | NSE |
| ARTHKUMBH VENTURES LLP | Bulk | Sell | 20 Apr 2026 | 327.70 | 945,855 | NSE |
| NEOMILE CORPORATE ADVISORY LIMITED | Bulk | Purchase | 20 Apr 2026 | 327.46 | 1,663,238 | NSE |
| L7 HITECH PRIVATE LIMITED | Bulk | Sell | 30 Mar 2026 | 338.45 | 264,780 | NSE |
| ARTHKUMBH VENTURES LLP | Bulk | Purchase | 30 Mar 2026 | 338.45 | 264,780 | NSE |
| L7 HITECH PRIVATE LIMITED | Bulk | Sell | 27 Mar 2026 | 353.07 | 371,675 | NSE |
Innovision Corporate Actions
Innovision Board Meetings
Innovision past and upcoming board meetings.
#Ex-Date | Purpose | Notes |
|---|---|---|
112 Aug 2026 | Quarterly Results | - |
228 May 2026 | Audited Results | (Revised) |
313 Apr 2026 | Quarterly Results | - |
Innovision Research Reports
Innovision research reports with share price targets, and buy/hold/sell recommendations from top brokers.
# Date | Broker Name | Target | Price When Recommended | Type | Upside | Change Since Recommendation | Links |
|---|---|---|---|---|---|---|---|
| 109 Mar 2026 | Hem Securities | - | - | IPO Subscribe | - | -% | |
| 208 Mar 2026 | SBI Securities | - | - | IPO Avoid | - | -% |
Innovision Corporate Filings
Innovision BSE corporate filings and AGM, press releases, insider trading & SAST, results and corporate actions.
| Date | Announcement Title | Details | Links |
|---|---|---|---|
| 22 Oct 2026 | Innovision Ltd - 544732 - Announcement under Regulation 30 (LODR) - Awarding of order(s) or contract(s) | Pursuant to Reg 30 of SEBI (LODR) intimation of receipt of workorder for LIMHA Fee Plaza in the state of Chatissgarh from NHAI | |
| 15 Oct 2026 | Innovision Ltd - 544732 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018 | Submission of Certificate as per Regulation 74(5) of DP Regulations, 2018 for the Quarter ended 30th September, 2026 | |
| 10 Oct 2026 | Innovision Ltd - 544732 - Announcement under Regulation 30 (LODR)-Resignation of Director | Clarification regarding the discrepancy remark raised dated 10th October, 2026 with respect to the corporate announcement. Please find attached file below. | |
| 09 Oct 2026 | Innovision Ltd - 544732 - Announcement under Regulation 30 (LODR)-Change in Directorate | Pursuant to Regulation 30 of SEBI LODR Regualtions, 2015, Company wishes to inform the Resignation of Non-Executive Independent Director -Mr.Pawan Kumar from the post of Directorship | |
| 09 Oct 2026 | Innovision Ltd - 544732 - Announcement under Regulation 30 (LODR)-Resignation of Director | Pursuant to SEBI LODR Regulations, 2015, Company wishes to inform the Resignation of Mr.Pawan Kumar from Post of Directorship-Non-Executive Independent Director |
Innovision Documents
Innovision Credit Ratings
Innovision credit ratings from CRISIL and leading rating agencies, assessing financial stability, investment grade, and related PDF documentation.
| Date | Rating Agency | Company Name | Description | Links |
|---|---|---|---|---|
| 09 Sep 2026 | crisil ratings | Innovision Limited | Innovision Limited:Update on Innovision Limited | Link |
Innovision Investor Presentations
Innovision investor presentations, including business updates, financial insights, and strategic initiatives.
Innovision - Company Profile
Innovision Board of Directors
Innovision Board of directors with salaries, total experience, and qualifications.
Website: www.innovision.co.in
About the company - Business Profile
Innovision Ltd. is an integrated pharmaceutical company with a focus on the manufacturing and marketing of a diverse range of pharmaceutical products. The company operates across multiple segments of the pharmaceutical value chain, including Contract Development and Manufacturing Organization (CDMO) services, domestic branded generics, and international generics. The company maintains a market position supported by its manufacturing infrastructure and a product portfolio that spans various therapeutic areas.
Key Points
- Key Facts: Innovision Ltd. (formerly known as Innova Captab Ltd.) was incorporated in 2005. It is headquartered in Mumbai, Maharashtra. The company is listed on both the BSE and NSE under the symbol INNOVACAP.
- Operations and Resources: The company operates manufacturing facilities, including a significant unit at Baddi, Himachal Pradesh. The manufacturing infrastructure is designed to handle multiple dosage forms, including tablets, capsules, dry syrups, and ointments.
- Ownership: The company is promoter-led, with the Aggarwal family holding a significant stake. It transitioned from a private entity to a publicly listed company following its Initial Public Offering (IPO) in late 2023.
- Market and Significance: Innovision serves a wide range of industries within the healthcare sector, providing manufacturing services to leading multinational and Indian pharmaceutical companies. Its strategic importance lies in its role as a large-scale manufacturer for diverse therapeutic categories including anti-infectives, analgesics, and dermatological products.
- Business Model: The business model is built on three main pillars: CDMO services for third-party brands, a domestic branded generics business focused on the Indian market, and an export business that targets semi-regulated and regulated international markets.
- Revenue Breakdown (FY 2025):
- CDMO Services: Contributed the largest portion of revenue at ₹1,052.8 crore.
- Domestic Branded Generics: Generated ₹167.2 crore.
- International Generics/Other Expenses: Accounts for approximately ₹167.1 crore.
- Geographical Revenue: While a significant portion of revenue is derived from the Indian market, the company has an expanding footprint in international markets across Southeast Asia, Africa, and the Middle East.
- Key Products and Advancements: The company offers a portfolio of over 600 products. Notable technological advancements include the establishment of an R&D center in Panchkula, which focuses on developing complex generic formulations and improving process efficiencies.
- Clients and Partnerships: The company serves as a manufacturing partner to several top-tier pharmaceutical firms in India, including Sun Pharmaceutical, Cipla, and Lupin.
- Employee Count: The company employs over 2,500 personnel across its manufacturing, R&D, and administrative divisions.
- Subsidiaries: Major subsidiaries include Univentis Medicare Limited, which focuses on the distribution and marketing of branded generic formulations.
- Strategic Initiatives: Current initiatives focus on the operationalization of a new manufacturing facility at Jammu to expand production capacity. The company is also prioritizing the expansion of its product pipeline in the chronic therapeutic segment and increasing its presence in regulated export markets.